KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Long-Term Debt Repayments (2016 - 2025)

Medtronic (MDT) has disclosed Long-Term Debt Repayments for 11 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Jan 2026, changed N/A year-over-year, with the annual reading at $6.0 billion for FY2023, 601100.0% up from the prior year.
  • Long-Term Debt Repayments hit $1.8 billion in Q4 2025 for Medtronic, up from $1.2 billion in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.9 billion in Q2 2023 to a low of $1.0 million in Q3 2021.
  • Historically, Long-Term Debt Repayments has averaged $1.2 billion across 4 years, with a median of $1.0 billion in 2021.
  • Biggest five-year swings in Long-Term Debt Repayments: tumbled 90.91% in 2021 and later soared 231000.0% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $1.0 million in 2021, then skyrocketed by 231000.0% to $2.3 billion in 2022, then grew by 26.74% to $2.9 billion in 2023, then tumbled by 39.64% to $1.8 billion in 2025.
  • Business Quant data shows Long-Term Debt Repayments for MDT at $1.8 billion in Q4 2025, $1.2 billion in Q3 2025, and $2.9 billion in Q2 2023.